1051-P: Cost-Effectiveness of Flash CGM Compared with SMBG—A Canadian Private-Payer Perspective

Introduction 10% basal insulin; and 6% MDI. Costs were taken from Canadian sources, and included flash CGM and SMBG acquisition costs, the costs to private payers of treating diabetes complications, and absenteeism costs. The primary outcome was cost per quality-adjusted life year (QALY). Results: For both T1DM and T2DM, flash CGM provided more QALYs than SMBG while reducing costs (Table). Scenario analyses were consistent with the base-case results. Conclusions: From a Canadian private payer perspective, flash CGM is cost effective compared with SMBG for all people living with diabetes. Disclosure S.B. Harris: Consultant; Abbott. Research Support; Boehringer-Ingelheim. Consultant; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company, Novo Nordisk, Sanofi. Research Support; Novartis AG. Consultant; Bayer Inc. S. Cimino: Consultant; Abbott, Boehringer-Ingelheim, Eisai Inc., Eli Lilly and Company, Merck Abbott. K. Szafranski: Consultant; Abbott, Novo Nordisk, Novartis Canada, CSL Behring, AbbVie Inc., Sanofi.